Abstract
5
We have developed the method to evaluate dynamic hyperinflation by the metronome-paced incremental hyperventilation (MPIH) technique, and demonstrated that both SABA and SAMA are effective for reducing dynamic hyperinflation in COPD. 6 We also demonstrated that the treatment with tiotropium (LAMA) for eight weeks partially reduced dynamic hyperinflation following the incremental hyperventilation and improved exercise capacity and health-related quality of life in COPD. 7 We hypothesized that the efficacy of SABA or SAMA on improving exercise capacity may be due to the relief of dynamic hyperinflation in stable COPD patients, and that it may also be additive to the efficacy of regular treatment with long-acting bronchodilators, including LAMA. 9 using the formulas described by Nishida et al 9 and Boren et al 10 , respectively.
Respiratory impedance was measured using an IOS (Masterscreen IOS;
Erich Jaeger, Hoechberg, Germany), as described previously. 11, 12 Respiratory impedance (Zrs) is characterized by two components: respiratory resistance (Rrs) and reactance (Xrs). Xrs undergoes a transition from negative to positive values as frequency (ƒ) increases. The resonant frequency (ƒres) was determined as the frequency at which Xrs crossed zero and the elastic and inertial forces were equal in magnitude and opposite. Rrs and Xrs at lower oscillation frequencies and Rrs at higher frequencies were evaluated at oscillation frequencies of 5 Hz (Rrs5 and Xrs5) and 20 Hz (Rrs20). We also measured mean values of Rrs5 and Xrs5 in separated inspiration and expiration of tidal breath, and evaluated the difference between mean expiratory and inspiratory resistance (ΔRrs5) and reactance (ΔXrs5).
Evaluation of dynamic hyperinflation following MPIH Dynamic hyperinflation was evaluated by metronome-paced hyperventilation, incrementally increasing the respiratory rate to 20, 30 and 40 breaths/min according to our previous reports. 6, 7 End-expiratory lung volume (EELV) by body plethysmography, inspiratory capacity (IC), and VC were measured immediately after breathing at resting respiratory rate for 30 s. Consequently, respiratory rate was increased to 20, 30 and 40 breaths/min in 30-s increments, and EELV, IC and VC were again measured immediately after metronome-paced hyperventilation for 30 s at each respiratory rate. Inspiratory capacity at resting respiratory rate was expressed as ICat rest. Inspiratory capacity at rates of 20, 30, and 40 breaths per minute were expressed as IC20, IC30, and IC40, respectively. 
Incremental shuttle walking test
The incremental shuttle walking test (ISWT) was conducted using the protocol described by Singh et al. 13 Briefly, patients were required to walk around a 10-meter course with the walking speed of each 10-meter shuttle dictated by an audio signal played on a compact disk. The test commenced at an initial speed of 0.5 meters per second, with one-minute increments of 0.17 meter per second. The test was terminated when the patients were too breathless to continue or failed to maintain the required speed on two consecutive shuttles. At the end of the test, patients rated their intensity of breathlessness by using a Borg 0-10 scale. 14 Oxygen saturation (PULSOX M2, Minolta Co. Ltd, Japan), heart rate, and blood pressure were measured prior to and at the termination of the test.
Data analysis
The values shown in the text, figures and tables represent means ± standard error of the mean (SEM). The data distribution of the variables in the two groups was first assessed with Bartlett's test. Data for the variables that showed a normal distribution were compared using the parametric Student's t-test. Data for the variables that did not show a normal distribution were compared using the nonparametric Mann-Whitney's U-test. The data distribution of the variables at baseline and after the inhalation of SABA or SAMA was first assessed with Bartlett's test. Data for the variables that showed a normal distribution were compared using the parametric paired t-test. Data for the variables that did not show a normal distribution were compared using the nonparametric Wilcoxon signed-rank test. Simple correlations between variables were examined by calculating Pearson's product correlation coefficient. All statistical analyses were performed using a Windows-compatible software (Stat Flex version 5.0; Artech, Osaka, Japan). A value of P<0.05 was considered to be significant for the results of all statistical analyses.
Results

Clinical characteristics and pulmonary function tests
The characteristics and pulmonary function at baseline in the two groups are shown in Table 1 . There were no significant differences in age, gender or body mass index between the two groups. There were no significant differences in VC, IC, FEV1, FEV1/FVC, RV, TLC, RV/TLC and DLCO between the two groups.
FEV1 was significantly increased compared to the baseline in both groups (Table   2 ). However, there was a significant difference between the increase in FEV1 in the SABA group and that in the SAMA group (0.14±0.02L vs. 0.08±0.02L, p<0.05). Rrs5, Rrs5-Rrs20 and ƒres were significantly decreased in the SABA group (Table 2 ). In contrast, there were no significant changes following inhalation of SAMA in these parameters of respiratory impedance.
Dynamic hyperinflation following MPIH
Inspiratory capacity was incrementally decreased as respiratory rate was incrementally increased in all patients before inhalation of SABA or SAMA. IC20, IC30 and IC40 significantly increased, and ICrest-30 and ICrest-40 significantly decreased in the SABA group (Figures 1 and 2) . IC40 significantly increased, and ICrest-40 significantly decreased in the SAMA group. These findings suggest that the additive efficacy of SABA on dynamic hyperinflation was superior to that of SAMA.
Incremental shuttle walking test
Walking distance of the ISWT was significantly increased following inhalation of SABA, but not following inhalation of SAMA (Table 3) We previously demonstrated that both SABA and SAMA are effective for reducing dynamic hyperinflation following MPIH, and that SABA is more effective than SAMA in COPD patients. 6 Previous studies have demonstrated that SABA is more effective for resting pulmonary function parameters than SAMA in stable COPD patients with a regular treatment with LAMA. 15, 16 In this study, the additive efficacy of SABA on airflow limitation, dynamic hyperinflation and exercise tolerance was superior to that of SAMA in stable COPD patients treated with LAMA. These findings suggest that SABA is better to use for relief of dyspnea as-needed in stable COPD patients regardless of regular treatment with LAMA.
Sukisaki et al. demonstrated that inhalation of procaterol hydrochloride
(SABA) enhances the effect of exercise training in the absence of any change in FEV1 during rehabilitation of COPD patients, and the effect lasted for at least four hours after inhalation. 17 They also demonstrated that the mean walking distance of the ISWT was significantly increased by 37 m following inhalation of SABA in 19 patients with moderate-to-severe COPD. In this study, it was significantly increased by 19.4 m following inhalation of SABA, which was smaller than the increase they demonstrated, and did not reach a statistically significant increase in the ISWT (>40 m) 18 and the minimum clinically important improvement for the ISWT (>47.5 m) 19 . The reason for the difference between the studies may be because we investigated the additive efficacy of SABA in stable COPD patients who had been treated with LAMA, and because very severe COPD patients were included in this study.
BSmax of the ISWT remained unchanged following inhalation of SABA, probably due to the fact that it was obtained at peak load during exercise, and walking distance also significantly increased. If Borg scale score would be obtained at the same load or at the same time during exercise, it is thus speculated that Borg scale score would decrease following inhalation of SABA.
Patients with COPD frequently report dyspnea related to everyday tasks. 20, 21 They often decrease their physical activity because exercise can worsen dyspnea. As a consequence, they tend to have problems including exercise deconditioning, relative social isolation, altered mood states, especially depression, muscle wasting, weight loss and osteoporosis. 5, 22 The progressive deconditioning associated with inactivity initiates a vicious cycle, with dyspnea becoming problematic at ever lower physical demands. 5 To address these problems, it is important to improve dyspnea in daily life leading to decreased physical activity. Therefore, it is noteworthy to pay attention to the additive efficacy of SABA for stable COPD patients together with pulmonary rehabilitation.
Single use of SABA before exercise, in addition to regular treatment with LAMA, may therefore be useful in stable COPD patients COPD increases the risk of cardiovascular disease by two-to threefold by itself. Furthermore, stimulation of β2-adrenergic receptors can produce resting sinus tachycardia and has the potential to precipitate cardiac rhythm disturbances in very susceptible patients, although this appears to be a remarkably rare event with inhaled therapy. 5 Hypokalemia occurs with β2-adrenergic stimulation as a result of intracellular shifts of potassium into skeletal muscle, 24 and has been associated with an increased risk for ventricular tachycardia and fibrillation in susceptible patients. 25 Elevated heart rate has been shown to be a strong independent risk factor for the development of cardiomyopathy, coronary artery disease, fatal myocardial infarction, sudden death, cardiovascular mortality, and total mortality. 26 In this study, there were no significant changes in maximum pulse rate and lowest SpO2 during exercise following the drug inhalation in either group. However, it should be noted that SABA occasionally has some adverse effects, particularly in patients with underlying ischemia, myocardial infarction, arrhythmia, or congestive heart failure.
The possible effects of tachyphylaxis of short-acting bronchodilators can be problematic in clinical practice. However, previous studies have demonstrated the effectiveness of long-term regular bronchodilator therapy with procaterol hydrochroride 27 and oxirtopium bromide 28 in stable COPD patients.
One limitation of this study is that the severity of COPD, assessed according 20 to the GOLD guidelines, tended to be higher in the SAMA group and this may have influenced the results. However, there were no significant differences in severity of COPD and the results at baseline between the groups. Another limitation of the study was the relatively small sample size, and further larger studies are required to confirm these results. 
